CoChat
Cited by 185

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors

Open access
Ceribelli, Michele, Kelly, Priscilla N., Shaffer, Arthur L., Wright, George W., Xiao, Wenming, Yang, Yibin, Mathews Griner, Lesley A., Guha, Rajarshi, Shinn, Paul, Keller, Jonathan M., Liu, Dongbo, Patel, Paresma R., Ferrer, Marc, Joshi, Shivangi, Nerle, Sujata, Sandy, Peter, Normant, Emmanuel, Thomas, Craig J., Staudt, Louis M. · 2014 · Proceedings of the National Academy of Sciences

Abstract

Significance: The activated B-cell–like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer that can only be cured in roughly 40% of cases. These malignant cells rely on the NF-κB signaling pathway for survival. Here, we report that genetic or pharmacologic interference with bromodomain and extraterminal domain (BET) chromatin proteins reduces NF-κB activity and ABC DLBCL viability. Unexpectedly, the mechanism involves inhibition of IκB kinase, the key cytoplasmic enzyme that activates the NF-κB pathway. The NF-κB pathway in ABC DLBCL is activated by B-cell receptor signaling, which can be blocked by the BTK kinase inhibitor ibrutinib. BET inhibitors synergized with ibrutinib to decrease growth of ABC DLBCL tumors in mouse models. BET inhibitors should be evaluated in ABC DLBCL clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1411701111

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Selective inhibition of BET bromodomains

    Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 1×

    “Recently, different small-molecule inhibitors of BET proteins have been developed that competitively interfere with BET protein binding to acetylated lysine residues of histones (11, 12).”
    Background
  • Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

    Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · cited 1×

    “Recent studies correlated the ability of BET inhibitors to downregulate gene expression to the presence of nearby superenhancers (SEs), which are large clusters of regulatory genomic regions that are enriched for the binding of BET proteins, mediator complex, and master regulators (17).”
    Background
  • RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

    Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870

  • Suppression of inflammation by a synthetic histone mimic

    Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563 · cited 3×

    “Our initial hypothesis was that BET inhibitors would be toxic to ABC DLBCL cells due to a direct negative effect on the transcription of NF-κB target genes, based on previous work suggesting this mechanism of action in macrophages (11).”
    Background
  • Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

    Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.003 · Cited by 735 · cited 3×

    “Indeed, SEs have been identified in DLBCL cells near genes encoding lymphoid-restricted transcription factors (18).”
    BackgroundMethodInfluential
  • Systematic discovery of multicomponent therapeutics

    Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620 · cited 1×

    “JQ1–drug interactions were ranked according to the “excess over the highest single agent” (HSA) method, a standard method used to discover synergistic combinations (23) (Fig.”
    Method

Cited by

See all 185

Metadata

Authors
Ceribelli, M., Kelly, P. N., Shaffer, A. L., Wright, G. W., Xiao, W., Yang, Y., Mathews Griner, L. A., Guha, R., Shinn, P., Keller, J. M., Liu, D., Patel, P. R., Ferrer, M., Joshi, S., Nerle, S., Sandy, P., Normant, E., Thomas, C. J., & Staudt, L. M.
Venue
Proceedings of the National Academy of Sciences
Published
2014-07-21
Volume
111
Issue
31
Pages
11365-11370
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2044874589
Cited by
185
References
6
FWCI
8.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.